Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis
Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis
复制标题
DOI：
10.1007/s00535-014-0934-2
复制
发表时间：
2015-01-01
影响因子：
6.3
通讯作者：
Shimatsu, Akira
中科院分区：
文献类型：
--
作者：
Ito, Tetsuhide;Igarashi, Hisato;Shimatsu, Akira
虽然神经内分泌肿瘤（NETs）是罕见的，但NET患者的数量正在增加。然而，在日本，自2005年以来没有关于NET的流行病学研究；因此，NET的流行程度仍然未知。我们于2005年报道了日本胃肠胰神经内分泌肿瘤（GEP-NETs）[胰腺神经内分泌肿瘤（PNETs）和胃肠道神经内分泌肿瘤（GI-NETs）]的流行病学。在这里，我们对2010年接受治疗的GEP-NETs患者进行了第二次全国调查。2010年，共有3379名患者接受了PNETs治疗，比2005年至2010年增加了1.2倍。估计患病率为2.69/10万，2010年年发病发生率为1.27/10万。无功能肿瘤(NF)-PNETs占65.5%，其次是胰岛素瘤（20.9%）和胃泌素瘤（8.2%）。有趣的是，NF-PNETs患者的数量自2005年以来增加了1.8倍。共有19.9%的患者在最初诊断时表现出远处转移；4.3%的患者合并多发性内分泌肿瘤1型（MEN-1），仅有4.0%的患者合并NF-PNETs。与此同时，估计有8088名患者接受了GI-NETs治疗，自2005年以来增加了1.8倍。估计患病率为6.42/10万，年发病率为3.51/10万。GI-NETs的位置各不相同：前肠占26.1%；中肠，3.6%；后肠，70.3%。在初诊时，远处转移和men1并发症的发生率分别为6.0%和0.42%。GI-NETs患者的类癌综合征发生率为3.2%。我们明确了2005 - 2010年日本GEP-NETs的流行病学变化。
Although neuroendocrine tumors (NETs) are rare, the number of patients with NET is increasing. However, in Japan, there have been no epidemiological studies on NET since 2005; thus, the prevalence of NET remains unknown.We reported the epidemiology of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [pancreatic neuroendocrine tumors (PNETs) and gastrointestinal neuroendocrine tumors (GI-NETs)] in Japan in 2005. Here, we conducted the second nationwide survey on patients with GEP-NETs who received treatment in 2010.A total of 3,379 patients received treatment for PNETs in 2010, representing a 1.2-fold increase in the number of patients from 2005 to 2010. The prevalence was estimated to be 2.69/100,000, with an annual onset incidence of 1.27/100,000 in 2010. Non-functioning tumor (NF)-PNETs comprised 65.5 % of cases followed by insulinoma (20.9 %) and gastrinoma (8.2 %). Interestingly, the number of patients with NF-PNETs increased similar to 1.8 fold since 2005. A total of 19.9 % of patients exhibited distant metastasis at initial diagnosis; 4.3 % had complications with multiple endocrine neoplasia type 1 (MEN-1), and only 4.0 % had NF-PNETs associated with MEN-1. Meanwhile, an estimated 8,088 patients received treatment for GI-NETs, representing a similar to 1.8-fold increase since 2005. The prevalence was estimated to be 6.42/100,000, with an annual onset incidence of 3.51/100,000. The locations of GI-NETs varied: foregut, 26.1 %; midgut, 3.6 %; and hindgut, 70.3 %. Distant metastasis and complications with MEN-1 were observed in 6.0 and 0.42 % at initial diagnosis, respectively. The frequency of carcinoid syndrome in patients with GI-NETs was 3.2 %.We clarified the epidemiological changes in GEP-NETs from 2005 to 2010 in Japan.